Figure 1
From: Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
(A) Serum IgM immunoreactivity to mushroom tyrosinase in healthy controls and in patients with melanoma or vitiligo, (B) Serum IgA immunoreactivity to mushroom tyrosinase in healthy controls and in patients with melanoma or vitiligo, (C) Serum IgG immunoreactivity to mushroom tyrosinase in healthy controls and in patients with melanoma or vitiligo. Red squares represent melanoma patients with metastatic disease, while brighter red squares with borders represent melanoma patients without metastases.